Elite Pharmaceuticals Secures FDA Approval for Generic Ropinirole Extended-Release Tablets for Parkinson's Disease
Key Insights
Elite Pharmaceuticals (search) received FDA approval for a generic version of Requip XL (search) (Ropinirole Extended-Release Tablets USP) in five strengths for treating Parkinson's disease symptoms.
The approved generic will be marketed under Elite's own Elite Laboratories (search) label, targeting a market with $10 million in annual U.S. sales.
Ropinirole functions as a non-ergoline dopamine agonist, representing Elite's continued focus on developing niche generic pharmaceutical products.
Elite Pharmaceuticals (search) announced on November 12, 2025, that it received FDA approval for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL (search)® (Ropinirole Extended-Release Tablets USP). The approval covers five tablet strengths: 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg, all designed to treat symptoms of Parkinson's disease.
Market Opportunity and Commercial Strategy
According to IQVIA data, the branded product and its equivalents generated total U.S. sales of $10 million for the twelve months ending September 2025. Elite plans to market and sell the generic ropinirole tablets under its Elite Laboratories (search), Inc. label, allowing the company to maintain direct control over the product's commercialization rather than licensing it to third-party organizations.
Drug Profile and Therapeutic Application
Ropinirole belongs to a class of drugs known as non-ergoline dopamine agonists, which work by mimicking the action of dopamine in the brain to help control movement symptoms associated with Parkinson's disease. The extended-release formulation provides sustained drug delivery, potentially improving patient compliance compared to immediate-release alternatives.
Company Background and Manufacturing Capabilities
Elite Pharmaceuticals (search) operates as a specialty pharmaceutical company focused on developing, manufacturing, and distributing niche generic products. The company maintains a cGMP and DEA registered facility in Northvale, New Jersey, for research, development, and manufacturing operations. Elite's product portfolio consists of both immediate-release and controlled-release solid oral dose products, which are marketed under the Elite Laboratories (search) label or through licenses granted to third-party pharmaceutical marketing and distribution organizations.
Financial Context and Market Position
The approval represents Elite's continued expansion in the specialty generic pharmaceutical sector. The company currently maintains a market capitalization of $678.2 million with an average trading volume of 1,219,993 shares. While the company demonstrates strong revenue growth, analysts note ongoing profitability challenges and cash flow inconsistencies that present risks for investors.